Quantcast
Last updated on April 16, 2014 at 10:58 EDT

Latest Stallergenes Stories

Allergy Pill For Hay Fever Approved By FDA
2014-04-03 05:24:55

redOrbit Staff & Wire Reports - Your Universe Online In a move that could replace allergy shots for some men and women, the US Food and Drug Administration (FDA) announced on Wednesday that it had approved the first tablet for the treatment of hay fever symptoms. The product is known as Oralair, according to USA Today’s Kim Painter, it will only work against certain types of grass pollens and will take multiple months before it starts working – meaning that it will not help...

2013-04-15 08:28:35

LIBERTY, Mo., April 15, 2013 /PRNewswire/ -- Antigen Laboratories, Inc., today announced that its parent company Planet Biopharmaceuticals, Inc. has signed a definitive agreement to be acquired by Ares Life Sciences (Ares), a healthcare focused investment group. Closing of the transaction is subject to certain closing conditions. Theron E. Odlaug, Planet Executive Chairman and CEO, commented, "We are looking forward to becoming a member of the Ares portfolio of life science companies and...

2011-10-11 00:00:00

BARCELONA, Spain, October 11, 2011 /PRNewswire/ -- Leading Specialty Pharmaceutical Company Consolidates Four On-Premise CRM Systems into One Stallergenes, the world leader in sublingual immunotherapy, has selected Veeva CRM to replace its existing conventional on-premise systems to support its worldwide sales force. Veeva CRM is today's #1 selling cloud-based CRM solution for the global pharmaceutical and biotech industry. Previously, Stallergenes utilised four...

2010-11-10 12:57:00

ANTONY, France, November 10, 2010 /PRNewswire-FirstCall/ -- Following the announcement that Wendel had entered exclusive negotiations with Ares Life Sciences on October 28, 2010, with a view to selling its entire stake (around 46%) in Stallergenes, the company's Works Council met on November 10, 2010. Stallergenes' Works Council having returned a positive consultative opinion at this meeting, Wendel and Ares Life Sciences proceeded to sign a firm transfer agreement. It is in...

2009-11-27 03:49:00

PARIS, November 27 /PRNewswire-FirstCall/ -- Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state. Oralair(R) is now registered in Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland,...

2009-08-26 12:01:00

PARIS, August 26 /PRNewswire-FirstCall/ -- - Net Profit Up 11% - Strong Research and Investment Effort - Positive net Financial Position - Annual Growth Guidance Maintained at 10% The Board of Directors, meeting on 25 August 2009 under the chairmanship of Albert Saporta approved the 2009 half year financial statements: In million Euros H1 2008 08/07 H1 2009 %CA Var.% %CA Sales...

2009-04-15 12:02:00

ANTONY, France, April 15 /PRNewswire-FirstCall/ -- - 1st Quarter 2009: Favourable Developments - Continuing Strong Growth: +15% (Organic* +14%) - Successful Launch of Oralair(R) in Germany - Net Financial Debt: Down 50% (EUR millions) 2008 08/07 2009 09/08 Million EUR % Sales % Million EUR % Sales % change Southern Europe (1) 37.9 78 14 41.8 74 10 Other EU...

2009-03-25 12:47:00

PARIS, March 25 /PRNewswire-FirstCall/ -- Hello, The investor meeting relating to the 2008 earnings and 2009 outlook has been webcasted. The presentation is available in English from the following link: http://www.thomson-webcast.net/uk/dispatching/?event_id=2ef87b3007af7a71 a2e0f120f7f05e9c&portal_id=55a3fb63ef049550bc3b4d09baf7bf5e (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field....

2009-03-24 13:49:00

ANTONY, France, March 24 /PRNewswire-FirstCall/ -- - Strong Growth in Results Sales up 16%, net Profit up 17% - Sound Financial Position - Proposed Increase in Dividend The Board of Directors, meeting on 23 March 2009 under the chairmanship of Albert SAPORTA, approved the 2008 consolidated financial statements: EUR millions 2007 07/06 2008 08/07 as % of % as % of %...

2009-01-15 12:10:00

ANTONY, France, January 15 /PRNewswire-FirstCall/ -- EUR millions 2007 07/06 2008 08/07 EUR % sales % change EUR % sales % change millions millions Southern Europe (1) 32.0 75 14 36.4 73 14 Other EU Countries 9.7 22 17 11.3 23 17 (2) Other markets 1.4 3 10 2.0 4...